{
    "clinical_study": {
        "@rank": "1469", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, multicenter, observational study will evaluate the sustained response in\n      patients with HBeAg positive chronic hepatitis B who are treated with Pegasys according to\n      standard of care and in line with the current local labeling in routine clinical practice in\n      Vietnam. Eligible patients will be followed for the duration of their treatment and for up\n      to 2 years thereafter."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  HBeAg-positive serologically proven chronic hepatitis B with or without cirrhosis\n\n          -  Elevated serum ALT > ULN (upper limit of normal) but </= 10 x ULN\n\n          -  Patients with no contra-indications to Pegasys therapy as detailed in the label\n\n          -  Written informed consent where local regulations allow or require it\n\n        Exclusion Criteria:\n\n          -  Patients should not receive concomitant therapy with telbivudine\n\n          -  Co-infection with hepatitis A, hepatitis B or HIV\n\n          -  Pregnant or breastfeeding women\n\n          -  Patients with depression/mental diseases\n\n          -  Neutrophil at baseline > 90.000/mm3\n\n          -  Abnormal T4 or TSH"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with HBeAg-positive chronic hepatitis B treated with Pegasys"
            }
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886300", 
            "org_study_id": "ML27807"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hanoi", 
                        "country": "Vietnam"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ho Chi Minh City", 
                        "country": "Vietnam", 
                        "zip": "District 5"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hochiminh city", 
                        "country": "Vietnam"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating Sustained Response in Subjects With HBeAg Positive Chronic Hepatitis B Receiving Therapy With Pegasys (Peginterferon Alfa-2a) in Vietnam", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health - Department of Scientific Technology and Training"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Sustained off-treatment response rate (based on HBeAg seroconversion) at 6 months after the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Sustained off-treatment response rate (based on HBeAg seroconversion) at 12 months after the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with suppression of HBV DNA to < 2,000 IU/mL during the observation period", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Incidence of HBsAg clearance", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Incidence of normalization of serum ALT", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014", 
        "why_stopped": "Due to out-of-date design and non-compliance."
    }
}